Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study
- 15 August 2018
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27 (3) , 1109-1119
Abstract
Recent studies suggested that olanzapine, together with dexamethasone and serotonin-3 receptor antagonist (5HT3RA), is effective in preventing chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC). This regimen is particularly useful in Southeast Asia (SEA) countries where resources are limited. We aimed to evaluate the cost-effectiveness of incorporating olanzapine into standard antiemetic regimens for the prevention of CINV in patients receiving HEC among SEA countries.Keywords
This publication has 22 references indexed in Scilit:
- A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomitingScientific Reports, 2014
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled StudyJournal of Pain and Symptom Management, 2014
- Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1Value in Health, 2012
- Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for SingaporeValue in Health Regional Issues, 2012
- Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III TrialJournal of Supportive Oncology, 2011
- Cost of illness of tuberculosis in Penang, MalaysiaPharmacy World & Science, 2008
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomitingCancer, 2003
- Patient Preferences Regarding Side Effects of Chemotherapy for Ovarian Cancer: Do They Change over Time?Gynecologic Oncology, 2002
- Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group StudyOncology, 1994